You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

17 Results
Guidelines and Advice
Status: Current
ID: GL 6-20
Version: 2
May 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Drugs Used:
oxaliplatin,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) - As Part of the MATRix Regimen in Newly Diagnosed Previously Untreated PCNSL
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
riTUXimab,
methotrexate,
cytarabine,
thiotepa
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Drugs Used:
oxaliplatin,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
oxaliplatin,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
oxaliplatin,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Hematologic
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Bortezomib - Previously Untreated Transplant Ineligible Mantle Cell Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
prednisone,
bortezomib,
riTUXimab,
DOXOrubicin,
cyclophosphamide,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2023
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
binimetinib (Unfunded),
encorafenib (Unfunded),
cetuximab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trastuzumab,
oxaliplatin,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab - First-line Treatment of Advanced Gastric, Esophageal, and Esophagogastric Junction Adenocarcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab,
oxaliplatin,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bevacizumab,
oxaliplatin,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Lenalidomide and Dexamethasone for Previously Untreated Multiple Myeloma Without Intent for Stem Cell Transplantation
ODB Limited Use
    lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or have not experienced progression while on a lenalidomide-based regimen in the treatment or maintenance setting, according to clinical criteria
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib (PDRP prior authorization),
lenalidomide,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2023

Pages